Subtopic Deep Dive
Ephedra Alkaloids in Obesity Pharmacotherapy
Research Guide
What is Ephedra Alkaloids in Obesity Pharmacotherapy?
Ephedra alkaloids in obesity pharmacotherapy refers to the use of ephedrine and pseudoephedrine from Ephedra plants for inducing thermogenesis and sympathomimetic effects to promote weight loss.
Ephedra alkaloids promote energy expenditure through adrenergic stimulation but carry risks of hypertension and cardiovascular events. Shekelle et al. (2003) meta-analysis of 19 studies found modest short-term weight loss (0.9 kg/month) with ephedra/ephedrine but doubled odds of adverse events (JAMA, 509 citations). FDA banned ephedra supplements in 2004 due to safety concerns documented in post-marketing reviews.
Why It Matters
Ephedra studies highlight cardiovascular risks of sympathomimetics, informing FDA bans and supplement regulations (Shekelle et al., 2003; Onakpoya et al., 2016). Ronis et al. (2017) report over 70% of Americans use supplements, with ephedra exemplifying hepatotoxicity and hypertension risks (330 citations). These cases guide safer pharmacotherapy development, as seen in synephrine alternatives (Haaz et al., 2006) and WADA prohibitions (Docherty, 2008).
Key Research Challenges
Cardiovascular Safety Assessment
Ephedra induces hypertension and tachycardia via sympathomimetic action, complicating risk-benefit analysis. Shekelle et al. (2003) reported doubled odds of heart palpitations and insomnia across trials. Long-term studies are absent, limiting chronic use evaluation (Onakpoya et al., 2016).
Efficacy in Sustained Weight Loss
Short-term weight reduction averages 0.9 kg/month but rebounds post-discontinuation. Shekelle et al. (2003) found no evidence for athletic performance gains. Heterogeneity in trial designs hinders meta-analytic conclusions (Haaz et al., 2006).
Regulatory and Hepatotoxicity Risks
Post-marketing withdrawals stem from liver injury and stroke cases. Ronis et al. (2017) link ephedra to unpredictable CYP450 metabolism. Distinguishing herbal adulteration from inherent toxicity remains unresolved (Tarantino et al., 2009).
Essential Papers
Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance
Paul G Shekelle, Mary Hardy, Sally C. Morton et al. · 2003 · JAMA · 509 citations
Context Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain. Objective To assess the efficacy and...
Adverse Effects of Nutraceuticals and Dietary Supplements
Martin J. J. Ronis, Kim Brint Pedersen, James Watt · 2017 · The Annual Review of Pharmacology and Toxicology · 330 citations
Over 70% of Americans take some form of dietary supplement every day, and the supplement industry is currently big business, with a gross of over $28 billion. However, unlike either foods or drugs,...
<i>Citrus aurantium</i> and synephrine alkaloids in the treatment of overweight and obesity: an update
Steffany Haaz, Kevin R. Fontaine, Gary Cutter et al. · 2006 · Obesity Reviews · 210 citations
Summary Obesity is a major health problem facing the developed and developing world. Efforts by individuals, health professionals, educators, and policy makers to combat the escalating trend of gro...
Herbal medicine for sports: a review
Maha Sellami, Olfa Slimeni, Andrzej Pokrywka et al. · 2018 · Journal of the International Society of Sports Nutrition · 171 citations
<i>The use of herbal medicinal products and supplements has increased</i> during last decades. At present, some herbs are used to enhance muscle strength and body mass. Emergent evidence suggests t...
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Igho Onakpoya, Carl Heneghan, Jeffrey K Aronson · 2016 · BMC Medicine · 164 citations
Most of the drugs that affect monoamine neurotransmitters licensed for the treatment of obesity over the past 65 years have been withdrawn because of adverse reactions. The reasons for withdrawal r...
Pharmacological Therapy of Obesity: Past, Present, and Future
David S. Weigle · 2003 · The Journal of Clinical Endocrinology & Metabolism · 149 citations
There is probably no medical condition for which a safe and effective form of pharmacotherapy is more highly desired than obesity.Neither is there a condition for which effective treatment would sp...
Management of Obesity as a Chronic Disease: Nonpharmacologic, Pharmacologic, and Surgical Options
Ken Fujioka · 2002 · Obesity Research · 145 citations
Abstract The successful management of obesity requires a long‐term approach that is tailored to an individual's lifestyle and needs. Initial treatment should focus on lifestyle modifications—dietar...
Reading Guide
Foundational Papers
Start with Shekelle et al. (2003, 509 citations) for core meta-analysis of 19 RCTs on weight loss (0.9 kg/month) and risks (OR=2.2); follow with Fujioka (2002) and Weigle (2003) for pharmacologic context.
Recent Advances
Study Onakpoya et al. (2016, 164 citations) on withdrawals due to monoamine effects; Ronis et al. (2017, 330 citations) on nutraceutical adverse events; Sellami et al. (2018) on sports herbal risks.
Core Methods
RCT meta-analyses (Shekelle 2003); post-marketing surveillance (Onakpoya 2016); sympathomimetic pharmacology reviews (Docherty 2008); CYP450 hepatotoxicity assays (Tarantino 2009).
How PapersFlow Helps You Research Ephedra Alkaloids in Obesity Pharmacotherapy
Discover & Search
Research Agent uses searchPapers('Ephedra alkaloids obesity safety') to retrieve Shekelle et al. (2003, 509 citations), then citationGraph reveals 1,200+ citing papers on bans, and findSimilarPapers uncovers Ronis et al. (2017) for supplement risks.
Analyze & Verify
Analysis Agent applies readPaperContent on Shekelle et al. (2003) to extract odds ratios (OR=2.2 for adverse events), verifyResponse with CoVe cross-checks against Onakpoya et al. (2016), and runPythonAnalysis computes meta-analysis forest plots using GRADE for moderate evidence quality on thermogenesis.
Synthesize & Write
Synthesis Agent detects gaps in long-term ephedra trials via contradiction flagging between Shekelle (2003) and Haaz (2006), while Writing Agent uses latexEditText for review drafts, latexSyncCitations for 50+ refs, and latexCompile for publication-ready PDFs with exportMermaid timelines of FDA bans.
Use Cases
"Extract weight loss effect sizes from ephedra RCTs and plot forest plot."
Research Agent → searchPapers → Analysis Agent → readPaperContent(Shekelle 2003) → runPythonAnalysis(pandas meta-analysis, matplotlib forest plot) → researcher gets CSV of ORs and GRADE-scored figure.
"Draft LaTeX review on ephedra bans citing Shekelle and Onakpoya."
Synthesis Agent → gap detection → Writing Agent → latexEditText(intro/methods) → latexSyncCitations(20 papers) → latexCompile → researcher gets compiled PDF with synced bibtex.
"Find GitHub code for ephedra pharmacokinetics simulations."
Research Agent → paperExtractUrls(Docherty 2008) → paperFindGithubRepo → githubRepoInspect → researcher gets PK models in Python for sympathomimetic simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ ephedra papers) → citationGraph → DeepScan(7-step safety analysis with GRADE) → structured report on risks. Theorizer generates hypotheses on synephrine as ephedra alternative from Haaz (2006) + Ronis (2017). DeepScan verifies claims across Shekelle (2003) citations with CoVe checkpoints.
Frequently Asked Questions
What is the definition of ephedra alkaloids in obesity pharmacotherapy?
Ephedrine and pseudoephedrine from Ephedra sinica induce thermogenesis and appetite suppression via beta-adrenergic stimulation for weight loss.
What methods assess ephedra efficacy and safety?
Meta-analyses of RCTs measure short-term weight loss (0.9 kg/month) and adverse events (OR=2.2); Shekelle et al. (2003) reviewed 19 trials with caffeine combinations.
What are key papers on ephedra in obesity?
Shekelle et al. (2003, JAMA, 509 citations) on efficacy/safety; Haaz et al. (2006) on synephrine alternatives (210 citations); Onakpoya et al. (2016) on withdrawals.
What open problems exist in ephedra research?
Lack of long-term RCTs, unpredictable hepatotoxicity via CYP450, and distinguishing herbal adulterants from pure alkaloids (Ronis et al., 2017; Tarantino et al., 2009).
Research Pharmacology and Obesity Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ephedra Alkaloids in Obesity Pharmacotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers